Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients

AIDS

Volumn 18, Issue 16, 2004, Pages 2205-2208

  Gianotti, Nicola ^a   Seminari, Elena ^a   Fusetti, Giuliana ^a   Salpietro, Stefania ^a   Boeri, Enzo ^b   Galli, Andrea ^a   Lazzarin, Adriano ^a   Clementi, Massimo ^a   Castagna, Antonella ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Diagnostica and Ricerca San Raffaele   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; DIDANOSINE; DIDANOSINE PLUS TENOFOVIR; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DATABASES, GENETIC; DIDANOSINE; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; GENE DELETION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PHOSPHONIC ACIDS;

EID: 7744223641     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200411050-00016     Document Type: Article

References (16)

1. Wainberg MA, Miller MD, Quan V, Salomon H, Mulato AS, Lamy PD, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87-94.
2. Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffman D, et al. Tenofovir resistance and resensitization. Antimicrob Agents Chemother 2003; 47:3478-3484.
3. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16:1227-1235.
4. Miller MD, Margot N, McColl D, Coakley D, Cheng A. Characteristic of virologic failure through 96 weeks among treatment naive patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV). In: Program and Abstracts of the 2nd International AIDS Society Conference on Pathogenesis and Treatment. Paris, France, 13-16 July 2003 [Abstract 553].
5. Gallant J, Rodriguez A, Weinberg W, Young B, Berger D, Lim ML, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. In: Program and Abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois, 14-17 September 2003 [Abstract H-1722a].
6. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of once daily abacavir (ABC), lamivudine (3TC) and tenofovir DF (TDF) in treatment-naive HIV-infected patients. In: Program and Abstracts of the 2nd International AIDS Society Conference on Pathogenesis and Treatment. Paris, France, 13-16 July 2003 [Abstract 43].
7. Jemsek J, Hutcherson P, Harper Jemsek E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 8-11 February 2004 [Abstract 51].
8. Stone C, Ait-Khaled M, Craig C, Griffin P, Tisdale M. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother 2004; 48:1413-1415.
9. Parikh U, Koontz D, Sluis-Cremer N, Hammond J, Bacheler L, Schinazi R, et al. K65R: a multinucleoside resistance mutation of increasing prevalence exhibits bi-directional phenotypic antagonism with TAM. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 8-11 February 2004 [Abstract 54].
10. White KL, Margot NA, Chen JM, Wang R, Pavelko M, Wrinet T, et al. The HIV-1 K65R RT mutant utilizes a combination of decreased incorporation and decreased excision to evade NRTI. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 8-11 February 2004 [Abstract 55].
11. Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D, Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase? AIDS 2004; 18:949-951.
12. Ruane P, Luber A, Akil B, Stryker R, Musikath P, Defoto J, et al. Factors influencing selection of K65R mutation among patients receiving tenofovir (TDF) containing regimens. In: Program and Abstracts of the 2nd International AIDS Society Conference on Pathogenesis and Treatment. Paris, France, 13-16 July 2003 [Abstract 582].
13. MacArthur RD, Crane LR, Alvarez D, Fairfax M, Richmond D, Curtis G. Factors associated with selection of the K65R mutation: a retrospective chart review. In: Program and Abstracts of the 2nd International AIDS Society Conference on Pathogenesis and Treatment. Paris, France, 13-16 July 2003 [Abstract 835].
14. Trotta MP, Bonfigli S, Ceccherini Silberstein F, Zinzi D, D'Arrigo R, Soldani F, et al. Clinical and genotypic correlates of the K65R mutation in an unselected cohort of HIV-infected persons naive for tenofovir. Antivir Ther 2004; 9:S168.
15. Boucher S, Recordon-Pinson P, Ragnaud JM, Dupon M, Fleury H, Maquelier B. K65R prevalence and genotypic patterns in patients failing tenofovir DF-containing regimens. In: Programme and Abstracts of the 2nd European HIV Drug Resistance Workshop: From Basic Science to Clinical Implications. Rome, Italy, 11-13 March 2004 [Abstract 51:P4.9].
16. Valer L, Gallego O, Garcia J, Bacheler L, de Mendoza C, Corral A, et al. Rate and clinical implications of selecting K65R. In: Programme and Abstracts of the 2nd European HIV Drug Resistance Workshop: From Basic Science to Clinical Implications. Rome, Italy, 11-13 March 2004 [Abstract 73:P5.5].